Skip to content

Stock-Based Comp at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$146M+1.4%
Amgen logo
AmgenAMGN
$75M-11.8%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$10.8M+48.8%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$19M+18.8%
Erasca, Inc. logo
Erasca, Inc.ERAS
$8.46M+26.0%
Immunome logo
ImmunomeIMNM
$7.95M+39.5%

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s stock-based comp?
IDEAYA Biosciences, Inc. (IDYA) reported stock-based comp of $14.54M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s stock-based comp changed year-over-year?
IDEAYA Biosciences, Inc.'s stock-based comp increased by 42.0% year-over-year, from $10.24M to $14.54M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s stock-based comp?
Over 4 years (2021 to 2025), IDEAYA Biosciences, Inc.'s stock-based comp has grown at a 53.8% compound annual growth rate (CAGR), from $8.24M to $46.12M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.